X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (5674) 5674
Newspaper Article (43) 43
Newsletter (40) 40
Magazine Article (10) 10
Publication (3) 3
Book Chapter (2) 2
Transcript (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (4884) 4884
melphalan - administration & dosage (3398) 3398
female (3346) 3346
male (3093) 3093
middle aged (2663) 2663
oncology (2198) 2198
adult (2128) 2128
melphalan (2119) 2119
aged (2035) 2035
antineoplastic combined chemotherapy protocols - therapeutic use (1960) 1960
hematology (1762) 1762
chemotherapy (1323) 1323
multiple myeloma - drug therapy (1320) 1320
treatment outcome (1185) 1185
transplantation (1133) 1133
multiple myeloma (1063) 1063
melphalan - therapeutic use (1054) 1054
combined modality therapy (968) 968
cyclophosphamide - administration & dosage (898) 898
transplantation, autologous (827) 827
antineoplastic combined chemotherapy protocols - administration & dosage (764) 764
cancer (738) 738
melphalan - adverse effects (723) 723
therapy (719) 719
animals (692) 692
stem-cell transplantation (680) 680
antineoplastic combined chemotherapy protocols - adverse effects (663) 663
prognosis (644) 644
bortezomib (635) 635
prednisone - administration & dosage (633) 633
multiple myeloma - therapy (628) 628
stem cells (619) 619
antineoplastic agents, alkylating - administration & dosage (618) 618
retrospective studies (615) 615
immunology (603) 603
adolescent (602) 602
survival (597) 597
disease-free survival (592) 592
care and treatment (583) 583
hematopoietic stem cell transplantation (580) 580
vincristine - administration & dosage (553) 553
survival rate (547) 547
aged, 80 and over (536) 536
dexamethasone - administration & dosage (535) 535
doxorubicin - administration & dosage (533) 533
follow-up studies (527) 527
survival analysis (519) 519
multiple myeloma - mortality (507) 507
antineoplastic agents - administration & dosage (502) 502
remission induction (461) 461
stem cell transplantation (458) 458
dexamethasone (443) 443
cyclophosphamide (441) 441
time factors (436) 436
dose-response relationship, drug (433) 433
etoposide - administration & dosage (427) 427
carmustine - administration & dosage (424) 424
drug therapy, combination (410) 410
child (404) 404
drug administration schedule (397) 397
surgery (393) 393
melanoma - drug therapy (392) 392
prednisone (390) 390
antineoplastic agents - therapeutic use (385) 385
dosage and administration (381) 381
mice (378) 378
bone-marrow-transplantation (373) 373
high-dose melphalan (366) 366
thalidomide (366) 366
medicine & public health (359) 359
child, preschool (355) 355
recurrence (349) 349
cytarabine - administration & dosage (348) 348
bone marrow transplantation (341) 341
transplantation conditioning - methods (341) 341
thalidomide - administration & dosage (338) 338
chemotherapy, cancer, regional perfusion (332) 332
health aspects (327) 327
hematopoietic stem cell transplantation - methods (324) 324
neoplasm staging (321) 321
multiple-myeloma (317) 317
prospective studies (316) 316
melanoma (313) 313
multiple myeloma - pathology (311) 311
research (304) 304
toxicity (304) 304
analysis (290) 290
hematopoietic stem cells (289) 289
infant (286) 286
bone-marrow transplantation (285) 285
boronic acids - administration & dosage (274) 274
pyrazines - administration & dosage (274) 274
trial (271) 271
risk factors (270) 270
tumor necrosis factor-alpha - administration & dosage (259) 259
chemotherapy, cancer, regional perfusion - methods (255) 255
high-dose chemotherapy (250) 250
antineoplastic agents, alkylating - therapeutic use (247) 247
drug therapy (247) 247
cisplatin - administration & dosage (246) 246
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (5343) 5343
Japanese (122) 122
Russian (114) 114
German (91) 91
French (63) 63
Spanish (41) 41
Polish (26) 26
Italian (22) 22
Chinese (12) 12
Dutch (9) 9
Czech (7) 7
Danish (4) 4
Norwegian (4) 4
Portuguese (4) 4
Swedish (4) 4
Hebrew (2) 2
Hungarian (2) 2
Serbian (2) 2
Slovak (2) 2
Finnish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The lancet oncology, ISSN 1470-2045, 2010, Volume 11, Issue 10, pp. 934 - 941
Journal Article
Blood, ISSN 1528-0020, 2012, Volume 119, Issue 20, pp. 4619 - 4624
Approximately 5-10% of diffuse large B-cell lymphomas (DLBCL) harbor a 8q24/MYC rearrangement (MYC+). We determined the prognostic significance of MYC... 
REARRANGEMENT | IMPACT | POOR-PROGNOSIS | T(14/18) | IN-SITU HYBRIDIZATION | CLASSIFICATION | HEMATOLOGY | EXPRESSION | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Podophyllotoxin - adverse effects | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Salvage Therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Dexamethasone - adverse effects | Male | Transplantation, Autologous | Cytarabine - adverse effects | Cisplatin - administration & dosage | Young Adult | Lymphoma, Large B-Cell, Diffuse - therapy | Melphalan - adverse effects | Immunotherapy | Treatment Failure | Podophyllotoxin - administration & dosage | Adult | Female | Chemotherapy, Adjuvant | Carmustine - adverse effects | Genes, myc - physiology | Dexamethasone - administration & dosage | Etoposide - adverse effects | Lymphoma, Large B-Cell, Diffuse - drug therapy | Ifosfamide - adverse effects | Rituximab | Etoposide - administration & dosage | Combined Modality Therapy | Cytarabine - administration & dosage | Lymphoma, Large B-Cell, Diffuse - mortality | Melphalan - administration & dosage | Ifosfamide - administration & dosage | Cisplatin - adverse effects | Aged | Hematopoietic Stem Cell Transplantation - methods | Antibodies, Monoclonal, Murine-Derived - adverse effects | Lymphoma, Large B-Cell, Diffuse - genetics | Carmustine - administration & dosage | Life Sciences | Biochemistry, Molecular Biology | Lymphoma, Large B-Cell, Diffuse | Podophyllotoxin | methods | Genes, myc | Cytarabine | genetics | administration & dosage | Melphalan | Antibodies, Monoclonal, Murine-Derived | Dexamethasone | drug therapy | Ifosfamide | Carmustine | therapy | Antineoplastic Combined Chemotherapy Protocols | Etoposide | physiology | Hematopoietic Stem Cell Transplantation | Cisplatin | adverse effects | mortality
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 2010, Volume 28, Issue 30, pp. 4630 - 4634
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 2005, Volume 23, Issue 36, pp. 9198 - 9207
Journal Article
British Journal of Haematology, ISSN 1365-2141, 07/2007, Volume 138, Issue 2, pp. 176 - 185
Journal Article
Blood, ISSN 1528-0020, 2012, Volume 120, Issue 1, pp. 9 - 19
Journal Article
JNCI : Journal of the National Cancer Institute, ISSN 0027-8874, 2014, Volume 106, Issue 8, pp. dju170 - dju170
This sixteenth biannual report of the Cochrane Haematological Malignancies Group highlights recently published randomized controlled trials (RCTs) in the field... 
SURVIVAL | OUTCOMES | ONCOLOGY | STEM-CELL TRANSPLANTATION | CHOP PLUS RITUXIMAB | Hematologic Neoplasms - therapy | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Lymphoma, Follicular - drug therapy | Primary Myelofibrosis | Nitrogen Mustard Compounds - administration & dosage | Humans | Pyrazines - administration & dosage | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Cytarabine - adverse effects | Cyclophosphamide - adverse effects | Melphalan - adverse effects | Vincristine - administration & dosage | Boronic Acids - administration & dosage | Carmustine - adverse effects | Doxorubicin - administration & dosage | Lymphoma, Non-Hodgkin - drug therapy | Prednisone - administration & dosage | Bortezomib | Etoposide - adverse effects | Lymphoma, Large B-Cell, Diffuse - drug therapy | Prednisone - adverse effects | Drug Administration Schedule | Lymphoma, Mantle-Cell - drug therapy | Rituximab | Etoposide - administration & dosage | Nitrogen Mustard Compounds - adverse effects | Cytarabine - administration & dosage | Randomized Controlled Trials as Topic | Melphalan - administration & dosage | Pyrazoles - administration & dosage | Bendamustine Hydrochloride | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Quality of Life | Vincristine - adverse effects | Antibodies, Monoclonal, Murine-Derived - adverse effects | Doxorubicin - adverse effects | Carmustine - administration & dosage
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2010, Volume 28, Issue 5, pp. 800 - 807
Journal Article
Biology of blood and marrow transplantation, ISSN 1083-8791, 2009, Volume 15, Issue 6, pp. 718 - 723
Lenalidomide is an agent that has shown great activity in patients with multiple myeloma (MM). However, studies have suggested that this drug negatively... 
Hematology, Oncology and Palliative Medicine | Myeloma | Stem cell mobilization | Autotransplant | COMBINATION THERAPY | NEWLY-DIAGNOSED MYELOMA | PHASE-2 | THALIDOMIDE | BORTEZOMIB | IMMUNOLOGY | CHEMOTHERAPY | TRANSPLANTATION | PLUS DEXAMETHASONE | REFRACTORY MYELOMA | HEMATOLOGY | MELPHALAN | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Hematopoietic Stem Cell Mobilization - methods | Humans | Middle Aged | Heterocyclic Compounds - pharmacology | Male | Transplantation, Autologous | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Recombinant Proteins | Filgrastim | Thalidomide - analogs & derivatives | Angiogenesis Inhibitors - administration & dosage | Multiple Myeloma - drug therapy | Granulocyte Colony-Stimulating Factor - antagonists & inhibitors | Antineoplastic Agents - adverse effects | Treatment Failure | Angiogenesis Inhibitors - therapeutic use | Vincristine - administration & dosage | Adult | Female | Antineoplastic Agents - pharmacology | Retrospective Studies | Angiogenesis Inhibitors - adverse effects | Multiple Myeloma - surgery | Bone Marrow - drug effects | Doxorubicin - administration & dosage | Multiple Myeloma - blood | Thalidomide - adverse effects | Ifosfamide - pharmacology | Dexamethasone - administration & dosage | Heterocyclic Compounds - administration & dosage | Risk Factors | Etoposide - pharmacology | Etoposide - administration & dosage | Combined Modality Therapy | Thalidomide - administration & dosage | Granulocyte Colony-Stimulating Factor - pharmacology | Leukapheresis | Ifosfamide - administration & dosage | Cyclophosphamide - pharmacology | Aged | Multiple Myeloma - radiotherapy | Thalidomide - therapeutic use | Peripheral Blood Stem Cell Transplantation | Granulocyte Colony-Stimulating Factor - administration & dosage | Chemotherapy | Care and treatment | Granulocyte colony-stimulating factor | Analysis | Multiple myeloma | Stem cells | Transplantation | Angiogenesis inhibitors | Cancer | Index Medicus
Journal Article
Blood, ISSN 1528-0020, 2008, Volume 112, Issue 10, pp. 4017 - 4023
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 2012, Volume 30, Issue 24, pp. 2946 - 2955
Journal Article